DKSH, an ingredients and chemicals distributor, was chosen for Novo Nordisk’s pharmaceutical grade compounds (quats) due to its logistical infrastructure and experience in the region.
Steve Profit, global sales and marketing director at Novo Nordisk Pharmatech, told us, “South East Asia is a fast-growing market with massive expansion happening within existing customers’ sites plus new business ventures in exciting new high growth regions.”
“To ensure that our customers worldwide get the best partner for key supplies possible, we wanted a partner with not only a local presence and excellent service but one that had a shared vision towards business ethics and product expertise to deliver excellence to our customers.”
DKSH is located within the region with an “omni-channel approach” for a “one-stop regional solution” for its clients. Profit explained that Asia-Pacific is the third largest pharmaceutical market in the world. He added that, in the region, “pharma sales will grow 8.4% by 2021.”
The quats include benzalkonium chloride, cetrimonium bromide, and cetrimide.
In a statement Tanja Schaffer, vice president, global pharmaceutical industry, DKSH, said that the quats it will be distributing are a “perfect fit” for its active pharmaceutical ingredients portfolio.